FUJIFILM Diosynth Biotechnologies and Regeneron Sign a 10-Year U.S. Manufacturing Agreement Valued at Over $3 Billion

FUJIFILM Diosynth Biotechnologies and Regeneron Sign a 10-Year U.S. Manufacturing Agreement Valued at Over $3 Billion

HOLLY SPRINGS, N.C.--(BUSINESS WIRE)--Apr 22, 2025-

Fujifilm lands $3bn Regeneron deal to produce mAbs

Citing “the need for manufacturing capacity” to meet “commercial portfolio and clinical pipeline,” Regeneron has entered a ten-year deal with Fujifilm Diosynth Biotechnologies (FDB).

# Regeneron Steps Up Manufacturing Investment and Record Revenue Growth Pave Path for Future Success!,

Regeneron Pharmaceuticals, Inc. has recently announced a significant investment aimed at bolstering its manufacturing capacities for its leading biologic medicines through a new agreement with FUJIFILM Diosynth Biotechnologies in North Carolina. This strategic partnership not only positions Regeneron to increase its production capabilities but also signifies a commitment to create high-paying jobs in the region, fostering an environment conduciv…